Drug Profile
ACI 35
Alternative Names: ACI-35; Anti-pTau vaccine - AC Immune; VAC-20121Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator AC Immune
- Developer AC Immune; Johnson & Johnson Innovative Medicine
- Class Alzheimer vaccines
- Mechanism of Action Immunostimulants; Tau protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Alzheimer's disease
Most Recent Events
- 01 Oct 2023 Janssen Pharmaceuticals is now called Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals website, October 2023)
- 28 Apr 2023 AC Immune plans a clinical trial in Alzheimer's disease in H2 of 2023
- 16 Aug 2022 ACI 35 is still in phase I trials for Alzheimer's-disease in Finalnd and United Kingdom (Johnson and Johnson pipeline, July 2022)